Page last updated: 2024-12-05
sk&f 91488
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
SK&F 91488: RN given refers to parent cpd; structure given in first source; PI: APT (80-92) (not an active MH record; now NM) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 5227 |
CHEMBL ID | 1230270 |
SCHEMBL ID | 12648461 |
MeSH ID | M0082859 |
Synonyms (32)
Synonym |
---|
CHEMBL1230270 |
NCGC00024626-01 |
lopac-s-145 |
tocris-0512 |
NCGC00015911-01 |
LOPAC0_001172 |
4DI , |
4-(dimethylamino)butyl imidothiocarbamate |
NCGC00024626-03 |
sk&f-91488 |
4-(dimethylamino)butyl carbamimidothioate |
sk&f 91488 |
carbamimidothioic acid, 4-(dimethylamino)butyl ester |
skf 91488 |
NCGC00024626-02 |
DB07106 |
homodimaprit |
skf-91488 |
68643-23-2 |
CCG-205246 |
1i4lvx494h , |
unii-1i4lvx494h |
AKOS006328360 |
NCGC00015911-02 |
NCGC00015911-03 |
NCGC00015911-04 |
[4-(carbamimidoylsulfanyl)butyl]dimethylamine |
SCHEMBL12648461 |
skf 91488 2hcl |
skf-91488; 4-(-dimethylamino)butyl ester 4(-n,n-dimethylamino)butylisothiourea |
DTXSID50988329 |
Q27096020 |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Conversely, following potentiation of the response to histamine with DTT, exposure of the tissue to desensitizing concentrations of histamine resulted in a dextral shift of the dose-response curve (dose ratio = 39." | ( Selective enhancement of histamine H1-receptor responses in guinea-pig ileal smooth muscle by 1,4-dithiothreitol. Donaldson, J; Hill, SJ, 1986) | 0.27 |
"Pretreatment with SKF 91488 shifted, in a dose-dependent fashion, the dose-response curves of the leakage of dye to histamine to lower concentrations in the trachea, main bronchi, and nasal mucosa." | ( Histamine N-methyltransferase inhibitor potentiates histamine- and antigen-induced airway microvascular leakage in guinea pigs. Maeyama, K; Morikawa, M; Nakazawa, H; Sasaki, H; Sekizawa, K; Watanabe, T; Yamauchi, K, 1995) | 0.29 |
"We report here that the dose-response curve of the histamine-stimulated phosphoinositide hydrolysis in the guinea pig cerebellar slices was shifted to the left when the slices were pretreated with SKF 91488 (100 microM), a specific inhibitor of histamine N-methyltransferase (HMT)." | ( Histamine N-methyltransferase regulates histamine-induced phosphoinositide hydrolysis in guinea pig cerebellum. Kitanaka, J; Kitanaka, N; Takemura, M; Terada, N; Tsujimura, T, 2001) | 0.31 |
" Histamine dose-dependently induced the contraction of sections of the guinea-pig small intestine, and the pretreatment of the tissue section with aminoguanidine (100 microM), a diamine oxidase inhibitor, but not with S-[4-(N,N-dimethylamino)butyl]isothiourea (100 microM), an inhibitor of histamine N-methyltransferase, shifted the dose-response curve of histamine-induced contraction to lower concentrations." | ( Expression of diamine oxidase (histaminase) in guinea-pig tissues. Kitanaka, J; Kitanaka, N; Takemura, M; Terada, N; Tsujimura, T, 2002) | 0.31 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (5)
Potency Measurements
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 6.3096 | 0.0251 | 20.2376 | 39.8107 | AID886 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 6.3096 | 0.0251 | 20.2376 | 39.8107 | AID886 |
phosphopantetheinyl transferase | Bacillus subtilis | Potency | 63.0957 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 0.0056 | 0.0010 | 6.0009 | 35.4813 | AID943 |
lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 12.5893 | 0.0200 | 10.7869 | 31.6228 | AID912 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Bioassays (3)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (32)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 8 (25.00) | 18.7374 |
1990's | 11 (34.38) | 18.2507 |
2000's | 6 (18.75) | 29.6817 |
2010's | 5 (15.63) | 24.3611 |
2020's | 2 (6.25) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.02
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.02) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 33 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |